



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, DC 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
08/487,283	06/07/95	EVANS	M ALX-152.1C1P

SETH A FIDEL
ALEXION PHARMACEUTICALS
25 SCIENCE PARK
SUITE 360
NEW HAVEN CT 06511

18M1/1224

EXAMINER

GAMBEL, P

ART UNIT	PAPER NUMBER
1806	<i>[Signature]</i>

DATE MAILED: 12/24/95

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND
TRADEMARKS
Washington, D.C. 20231

08/487283

DEA/FCE-1994

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

EXAMINER	
ART UNIT	PAPER NUMBER
7	

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821-1.825. However, this application fails to comply with the requirements set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

The communication filed on 10/26/95 is not fully responsive to the communication mailed 8/25/95 for the reasons(s) set forth on the attached Notice to Comply with the Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequences Disclosures.

See marked up copy of Raw Sequence Listing.

Applicant must provide: (1) An initial or substitute computer readable form (CRF) copy of the Sequence Listing and (2) A statement that the context of the paper and computer readable copies are the same and where applicable include no new matter, as required by 37 CFR 1.821 (b), (d), (e), (f) or (g).

Since the response appears to be bona fide, but through an apparent oversight or inadvertence failed to provide a complete response, applicant is required to complete the response within a time limit of one month from the date of this letter, 37 CFR 1.135(c). Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Applicant is requested to return a copy of the attached Notice To Comply with the response.

Applicant is required to fulfill these requirements.

Any inquiry concerning this communication should be directed to Examiner Phillip Gambel, Art Unit 1806, whose telephone number is (703) 308-3997.



12/19/96

08/487283

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821.
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- 7. Other: _____

Applicant must provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123
For CRF submission help, call (703) 308-4212
For PatentIn software help, call (703) 308-6856

08/487283

Please return a copy of this notice with your response.